Oral ensartinib is effective in patients with co-existing ALK fusion and point mutations

oleh: Zhijian Yao, Xin Li, Xiyu An, Dongyu Cui

Format: Article
Diterbitkan: Elsevier 2023-09-01

Deskripsi

No description available for this item.